DUBLIN, July 3, 2023 /PRNewswire/ — The “Viral & Non-Viral Vector Manufacturing Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027” report has been added to ResearchAndMarkets.com’s offering.
The global viral & non-viral vector manufacturing market is anticipated to observe impressive growth during the forecast period, 2023-2027.
The major factors include the rising prevalence of fatal diseases, the growing prominence of gene and cell therapy products, and extensive development in technology, which are propelling the growth of the market. Vectors are tools for gene delivery, which deliver genetic material into the nucleic cell.
They are of two types, viral and non-viral vectors. Viral vectors are commonly used delivery vehicles in FDA-approved gene therapies, whereas non-viral are still studied for their safety and efficacy.
The other factors supporting the market’s growth are the extensive research and development, an increasing number of patients, an increasing number of clinical studies, various investments by private as well public sectors, increasing prevalence of vector-based gene and cell treatments, the growing number of collaborations between companies, and the high demand for customized medications.
Rising Prevalence of Fatal Diseases
The increasing occurrence of genetic disorders, cancers, and infectious diseases, such as diabetes, down syndrome, flu, liver cancer, Alzheimer’s disease, cardiovascular diseases, and others, across the globe are bolstering the growth of the market. According to the WHO, Cardiovascular diseases (CVDs) are the leading cause of death worldwide, taking approximately 17.9 million lives each year.
As per WHO, cancer is a leading cause of death, reporting almost 10 million deaths, or nearly one in six deaths in 2020. Owing to the increasing number of patients suffering from these fatal diseases, the demand for vectors for treatment is rising. For instance, in 2019, the FDA approved MVA (Modified Vaccinia virus Ankara), under the market name Jynneos, to prevent both smallpox and monkeypox.
Growing Prominence of Gene and Cell Therapy Products
Gene therapy is a method to treat or prevent disease with the help of genetic material. Advanced gene and cell therapies, with the use of vectors, have considerably impacted the field of biomedicine. After various research, it is found that the vectors are not only used to prevent or treat specific diseases, but with the genetic information they have, they can directly target the cause of the disease and can alter the way a cell functions.
The rising prevalence of vector-based gene and cell treatments is also a contributing factor to the growth of the market. Therefore, numerous innovator companies are actively involved in the development and production of viral vectors and non-viral vectors for cell and gene therapies. For instance, in 2022, the USFDA approved the second CAR-T therapy named CARVYKTIT, developed by Johnson and Johnson, which is used for the treatment of relapsed or refractory multiple myeloma.
- Catalent, Inc.
- FUJIFILM Holdings Corporation
- Danaher Corporation
- Genscript Biotech Corporation
- Lonza Group AG
- Merck KGaA Inc.
- Oxford Biomedica plc
- Sartorius AG
- Takara Bio Inc.
- Thermo Fisher Scientific Inc
by Vector Type:
- Viral Vector
- Adenoviral Vector
- Retroviral Vector
- Lentiviral Vector
- Vaccinia Viral Vector
- Non-Viral Vector
- Plasmid DNA
- Lipid-Based Non-Viral Vector
- Polymer-Based Non-Viral Vector
- Genetic Disease
- Infectious Disease
- Cardiovascular Diseases
- Gene Therapy
- Cell Therapy
- North America
- United States
- South Korea
- Europe & CIS
- United Kingdom
- South America
- Middle East & Africa
- South Africa
- Saudi Arabia
For more information about this report visit https://www.researchandmarkets.com/r/2w5tns
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-viral–non-viral-vector-manufacturing-market-2023-to-2027-growing-prominence-of-gene-and-cell-therapy-products-fuels-the-sector-301869016.html
SOURCE Research and Markets